Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

518 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Human equilibrative nucleoside transporter-1 expression is a predictor in patients with resected pancreatic cancer treated with adjuvant S-1 chemotherapy.
Okamura Y, Yasukawa S, Narimatsu H, Boku N, Fukutomi A, Konishi M, Morinaga S, Toyama H, Kaneoka Y, Shimizu Y, Nakamori S, Sata N, Yamakita K, Takahashi A, Kainuma O, Hishinuma S, Yamaguchi R, Nagino M, Hirano S, Yanagisawa A, Mori K, Uesaka K. Okamura Y, et al. Among authors: morinaga s. Cancer Sci. 2020 Feb;111(2):548-560. doi: 10.1111/cas.14258. Epub 2019 Dec 19. Cancer Sci. 2020. PMID: 31778273 Free PMC article.
Immunohistochemical analysis of human equilibrative nucleoside transporter-1 (hENT1) predicts survival in resected pancreatic cancer patients treated with adjuvant gemcitabine monotherapy.
Morinaga S, Nakamura Y, Watanabe T, Mikayama H, Tamagawa H, Yamamoto N, Shiozawa M, Akaike M, Ohkawa S, Kameda Y, Miyagi Y. Morinaga S, et al. Ann Surg Oncol. 2012 Jul;19 Suppl 3:S558-64. doi: 10.1245/s10434-011-2054-z. Epub 2011 Sep 13. Ann Surg Oncol. 2012. PMID: 21913012
Risk factors for 6-month continuation of S-1 adjuvant chemotherapy for resected pancreatic cancer.
Aoyama T, Katayama Y, Murakawa M, Asari M, Kanazawa A, Higuchi A, Shiozawa M, Kobayashi S, Ueno M, Morimoto M, Ohkawa S, Akaike M, Yamamoto N, Yoshikawa T, Rino Y, Masuda M, Morinaga S. Aoyama T, et al. Among authors: morinaga s. Cancer Chemother Pharmacol. 2014 Dec;74(6):1235-40. doi: 10.1007/s00280-014-2601-y. Epub 2014 Oct 9. Cancer Chemother Pharmacol. 2014. PMID: 25297990
Safety and feasibility of S-1 adjuvant chemotherapy for pancreatic cancer in elderly patients.
Aoyama T, Katayama Y, Murakawa M, Atsumi Y, Yamaoku K, Kanazawa A, Higuchi A, Shiozawa M, Kobayashi S, Ueno M, Morimoto M, Yamamoto N, Oshima T, Yoshikawa T, Rino Y, Masuda M, Morinaga S. Aoyama T, et al. Among authors: morinaga s. Cancer Chemother Pharmacol. 2015 Jun;75(6):1115-20. doi: 10.1007/s00280-015-2736-5. Epub 2015 Mar 29. Cancer Chemother Pharmacol. 2015. PMID: 25821166
518 results